In conclusion, the future outlook for EGFR-TKI-induced cardiotoxicity involves personalized treatment approaches, improved risk prediction, and more effective therapeutic strategies, ultimately enhancing the quality of life and survival prospects for individuals with EGFR-mutated cancers. Here, EGFR is linked to cancer.